Profile data is unavailable for this security.
About the company
2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
- Revenue in USD (TTM)100.39m
- Net income in USD-217.57m
- Incorporated2021
- Employees274.00
- Location2Seventy Bio Inc60 Binney StreetCAMBRIDGE 02210United StatesUSA
- Phone+1 (339) 499-9300
- Fax+1 (302) 636-5454
- Websitehttps://www.2seventybio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ovid Therapeutics Inc | 391.69k | -52.34m | 226.27m | 40.00 | -- | 2.58 | -- | 577.68 | -0.7415 | -0.7415 | 0.0056 | 1.24 | 0.0026 | -- | -- | 9,792.25 | -34.98 | -20.78 | -37.27 | -23.27 | -- | -- | -13,362.34 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Adverum Biotechnologies Inc | 3.60m | -117.17m | 228.30m | 121.00 | -- | 1.34 | -- | 63.42 | -11.62 | -11.62 | 0.3571 | 8.23 | 0.015 | -- | -- | 29,752.07 | -48.68 | -36.39 | -55.24 | -39.04 | -- | -- | -3,254.58 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -37.54m | 230.28m | 10.00 | -- | 1.93 | -- | -- | -0.6375 | -0.6375 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -22.78 | -36.79 | -25.71 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1123 | -- | -- | -- | 39.47 | -- | -- | -- |
| AVITA Medical Inc | 50.14m | -35.38m | 230.85m | 207.00 | -- | 4.70 | -- | 4.60 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.40 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Conduit Pharmaceuticals Inc | 0.00 | -1.75m | 232.56m | -- | -- | -- | 1,933.68 | -- | -0.0031 | -0.0031 | 0.00 | -0.0149 | 0.00 | -- | -- | -- | -2.35 | -- | -2.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 9,201.37 | -- | -- | -- |
| AC Immune SA | 16.23m | -59.49m | 236.09m | 133.00 | -- | 1.34 | -- | 14.54 | -0.704 | -0.704 | 0.1912 | 1.78 | 0.0803 | -- | 1.92 | 122,064.00 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Boundless Bio Inc | 0.00 | -49.43m | 237.07m | 72.00 | -- | -- | -- | -- | -2.22 | -2.22 | 0.00 | 5.42 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| 2Seventy Bio Inc | 100.39m | -217.57m | 237.57m | 274.00 | -- | 0.9182 | -- | 2.37 | -4.41 | -4.41 | 2.04 | 5.04 | 0.1643 | -- | 5.84 | 366,375.90 | -35.61 | -- | -40.20 | -- | 83.15 | 91.76 | -216.73 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Verastem Inc | 0.00 | -87.37m | 243.21m | 73.00 | -- | 4.23 | -- | -- | -4.07 | -4.07 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -71.39 | -62.70 | -88.82 | -75.18 | -- | -- | -- | -406.17 | -- | -- | 0.3379 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Puma Biotechnology Inc | 235.64m | 21.59m | 247.30m | 185.00 | 11.36 | 4.57 | 7.47 | 1.05 | 0.4515 | 0.4515 | 4.96 | 1.12 | 1.04 | 10.80 | 5.23 | 1,273,714.00 | 9.54 | -12.21 | 15.66 | -20.53 | 73.40 | 78.78 | 9.16 | -11.79 | 1.50 | 3.10 | 0.6509 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Coherus Biosciences Inc | 257.24m | -237.89m | 247.43m | 306.00 | -- | -- | -- | 0.9618 | -2.56 | -2.56 | 2.74 | -1.72 | 0.4633 | 3.14 | 1.39 | 840,666.70 | -42.85 | -21.43 | -74.34 | -29.32 | 38.19 | 79.01 | -92.48 | -36.56 | 1.24 | -4.77 | 1.69 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| XBiotech Inc | 0.00 | -24.56m | 249.09m | 82.00 | -- | 1.14 | -- | -- | -0.8068 | -0.8068 | 0.00 | 7.19 | 0.00 | -- | -- | 0.00 | -10.39 | 31.88 | -10.62 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.00 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Xeris Biopharma Holdings Inc | 163.91m | -62.26m | 250.01m | 377.00 | -- | -- | -- | 1.53 | -0.4525 | -0.4525 | 1.19 | -0.0491 | 0.4914 | 0.9012 | 4.68 | 434,785.20 | -18.66 | -43.60 | -24.99 | -56.57 | 82.52 | 78.23 | -37.98 | -143.08 | 1.23 | -2.01 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Fennec Pharmaceuticals Inc | 21.25m | -16.05m | 250.40m | 36.00 | -- | -- | -- | 11.78 | -0.6042 | -0.6042 | 0.7994 | -0.43 | 0.79 | 0.9217 | 4.10 | -- | -59.64 | -73.43 | -77.06 | -84.32 | 94.08 | -- | -75.50 | -383.28 | 3.27 | -3.90 | 1.63 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Century Therapeutics Inc | 2.24m | -136.67m | 252.56m | 152.00 | -- | 1.02 | -- | 113.00 | -2.30 | -2.30 | 0.0377 | 3.06 | 0.0053 | -- | -- | 14,703.95 | -32.26 | -- | -34.19 | -- | -- | -- | -6,115.12 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
Data as of Apr 24 2024. Currency figures normalised to 2Seventy Bio Inc's reporting currency: US Dollar USD
63.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kynam Capital Management LPas of 31 Dec 2023 | 5.95m | 11.60% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 4.60m | 8.97% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 4.47m | 8.71% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 3.94m | 7.68% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 3.50m | 6.82% |
| Baker Bros. Advisors LPas of 31 Dec 2023 | 2.50m | 4.87% |
| Millennium Management LLCas of 31 Dec 2023 | 2.34m | 4.55% |
| Casdin Capital LLCas of 26 Mar 2024 | 2.02m | 3.93% |
| Madison Avenue Partners LPas of 31 Dec 2023 | 1.75m | 3.42% |
| Engine Capital Management LPas of 31 Dec 2023 | 1.49m | 2.91% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
